<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02347189</url>
  </required_header>
  <id_info>
    <org_study_id>10154745DOC</org_study_id>
    <nct_id>NCT02347189</nct_id>
  </id_info>
  <brief_title>Melody PB1016 Surveillance Study</brief_title>
  <official_title>Melody(TM) Transcatheter Pulmonary Valve PB1016 Surveillance Study Implantation of the Medtronic Melody Transcatheter Pulmonary Valve PB1016 Using the Ensemble(TM) Transcatheter Delivery System in Patients With Dysfunctional RVOT Conduits</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Heart Valves</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-randomized, multi-center, prospective surveillance study to investigate and assess the
      residual risks, and to confirm the currently established safety and performance of the Melody
      TPV PB1016.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Acceptable TPV Hemodynamic Function At 6 Months</measure>
    <time_frame>6 Months</time_frame>
    <description>Acceptable TPV hemodynamic function at six months after successful TPV implantation which is determined as a composite of the following:
Mean Right Ventricular Outflow Tract (RVOT) gradient is less than or equal to 30 mmHg as measured by Continuous-wave Doppler (CW Doppler) echocardiography, and
Severity of pulmonary regurgitation less than moderate by CW Doppler echocardiography, and
Free from RVOT conduit reoperation or catheter re-intervention on the TPV at six months post-TPV implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Acceptable TPV Hemodynamic Function At 1 Year</measure>
    <time_frame>1 Year</time_frame>
    <description>Acceptable TPV hemodynamic function at 1 year after successful TPV implantation which is determined as a composite of the following:
Mean RVOT gradient is ≤ 30 mmHg as measured by CW Doppler
Severity of pulmonary regurgitation is less than moderate by Doppler echocardiography
Free from RVOT conduit reoperation or catheter re-intervention on the TPV at 1 year post-TPV implantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Acceptable TPV Hemodynamic Function at 2 Years</measure>
    <time_frame>2 Years</time_frame>
    <description>Acceptable TPV hemodynamic function at 2 years after successful TPV implantation which is determined as a composite of the following:
Mean RVOT gradient is ≤ 30 mmHg as measured by CW Doppler
Severity of pulmonary regurgitation is less than moderate by Doppler echocardiography
Free from RVOT conduit reoperation or catheter re-intervention on the TPV at 2 years post-TPV implantation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Subjects With Serious Adverse Events, Related Adverse Events and Free From Stent Fracture, Intervention on the TPV and Death</measure>
    <time_frame>6 Months, 1 Year, 2 Years</time_frame>
    <description>Serious procedure-related adverse events
Serious device-related adverse events at 6 months, 1 year and 2 years post-implant
Freedom from stent fracture at 6 months, 1 year and 2 years post-implant
Freedom from catheter re-intervention on the Melody TPV PB1016 at 6 months, 1 year and 2 years post-implant
Freedom from RVOT conduit reoperation at 6 months, 1 year and 2 years post-implant
Freedom from death (all-cause, procedural, and device-related) at 6 months, 1 year and 2 years post-implant</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subjects With Successful Procedure</measure>
    <time_frame>At Time Of Procedure</time_frame>
    <description>A successful implant is defined as follows:
Melody TPV PB1016 is fixated within the desired location
RV-PA peak-to-peak gradient measured in the catheterization lab after Melody TPV PB1016 implantation is &lt; 35 mmHg
No more than trace/trivial pulmonary regurgitation by angiography
Subject is free from explantation of the Melody TPV PB1016 at 24 hours post-implant.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Dysfunctional RVOT Conduits in Patients With Congenital Heart Defects</condition>
  <arm_group>
    <arm_group_label>Melody TPV PB1016</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Melody Transcatheter Pulmonary Valve PB1016</intervention_name>
    <arm_group_label>Melody TPV PB1016</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient eligible to receive Melody TPV PB1016 per current Instructions for Use (IFU)
             indications at time of study enrollment

          -  Patient (or patient's legally authorized representative) is willing to consent to
             participate in the study and will commit to completion of all follow-up requirements.

        Exclusion Criteria:

          -  Implantation in the aortic, tricuspid, or mitral position

          -  Venous anatomy unable to accommodate a 22-Fr size introducer sheath

          -  Obstruction of the central veins

          -  Clinical or biological signs of infection including active endocarditis

          -  History of intravenous substance abuse

          -  Currently participating in an investigational drug or device study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Childrens Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Childrens and Regional Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landes-Kinderklinik</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stollery Childrens Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2015</study_first_posted>
  <results_first_submitted>September 20, 2017</results_first_submitted>
  <results_first_submitted_qc>October 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 29, 2017</results_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Melody PB1016 Subjects Consented (i.e. Enrolled)</title>
          <description>This study is comprised of a single arm of subjects consented (i.e. enrolled) into the trial. All enrolled subjects were intended to be treated with the Melody TPV PB1016 device. Not all subjects enrolled ultimately received the device.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Catheterized</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Implanted</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Implanted &gt; 24 Hours</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No implant attempted of study device</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No primary outcome data available</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects consented</population>
      <group_list>
        <group group_id="B1">
          <title>Melody PB1016 Subjects Consented (i.e. Enrolled)</title>
          <description>This study is comprised of a single arm of subjects consented (i.e. enrolled) into the trial. All enrolled subjects were intended to be treated with the Melody TPV PB1016 device. Not all subjects enrolled ultimately received the device.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.2" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Acceptable TPV Hemodynamic Function At 6 Months</title>
        <description>Acceptable TPV hemodynamic function at six months after successful TPV implantation which is determined as a composite of the following:
Mean Right Ventricular Outflow Tract (RVOT) gradient is less than or equal to 30 mmHg as measured by Continuous-wave Doppler (CW Doppler) echocardiography, and
Severity of pulmonary regurgitation less than moderate by CW Doppler echocardiography, and
Free from RVOT conduit reoperation or catheter re-intervention on the TPV at six months post-TPV implantation</description>
        <time_frame>6 Months</time_frame>
        <population>28 subjects successfully implanted for greater than 24 hours (out of 30 total) had evaluable data at 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Implanted &gt; 24 Hours Cohort</title>
            <description>Subjects included in this analysis were those who were successfully implanted with a Melody TPV PB1016 for greater than 24 hours and had evaluable data at 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Acceptable TPV Hemodynamic Function At 6 Months</title>
          <description>Acceptable TPV hemodynamic function at six months after successful TPV implantation which is determined as a composite of the following:
Mean Right Ventricular Outflow Tract (RVOT) gradient is less than or equal to 30 mmHg as measured by Continuous-wave Doppler (CW Doppler) echocardiography, and
Severity of pulmonary regurgitation less than moderate by CW Doppler echocardiography, and
Free from RVOT conduit reoperation or catheter re-intervention on the TPV at six months post-TPV implantation</description>
          <population>28 subjects successfully implanted for greater than 24 hours (out of 30 total) had evaluable data at 6 months.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Acceptable TPV Hemodynamic Function At 1 Year</title>
        <description>Acceptable TPV hemodynamic function at 1 year after successful TPV implantation which is determined as a composite of the following:
Mean RVOT gradient is ≤ 30 mmHg as measured by CW Doppler
Severity of pulmonary regurgitation is less than moderate by Doppler echocardiography
Free from RVOT conduit reoperation or catheter re-intervention on the TPV at 1 year post-TPV implantation.</description>
        <time_frame>1 Year</time_frame>
        <posting_date>06/2019</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Acceptable TPV Hemodynamic Function at 2 Years</title>
        <description>Acceptable TPV hemodynamic function at 2 years after successful TPV implantation which is determined as a composite of the following:
Mean RVOT gradient is ≤ 30 mmHg as measured by CW Doppler
Severity of pulmonary regurgitation is less than moderate by Doppler echocardiography
Free from RVOT conduit reoperation or catheter re-intervention on the TPV at 2 years post-TPV implantation.</description>
        <time_frame>2 Years</time_frame>
        <posting_date>06/2019</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects With Serious Adverse Events, Related Adverse Events and Free From Stent Fracture, Intervention on the TPV and Death</title>
        <description>Serious procedure-related adverse events
Serious device-related adverse events at 6 months, 1 year and 2 years post-implant
Freedom from stent fracture at 6 months, 1 year and 2 years post-implant
Freedom from catheter re-intervention on the Melody TPV PB1016 at 6 months, 1 year and 2 years post-implant
Freedom from RVOT conduit reoperation at 6 months, 1 year and 2 years post-implant
Freedom from death (all-cause, procedural, and device-related) at 6 months, 1 year and 2 years post-implant</description>
        <time_frame>6 Months, 1 Year, 2 Years</time_frame>
        <posting_date>06/2019</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subjects With Successful Procedure</title>
        <description>A successful implant is defined as follows:
Melody TPV PB1016 is fixated within the desired location
RV-PA peak-to-peak gradient measured in the catheterization lab after Melody TPV PB1016 implantation is &lt; 35 mmHg
No more than trace/trivial pulmonary regurgitation by angiography
Subject is free from explantation of the Melody TPV PB1016 at 24 hours post-implant.</description>
        <time_frame>At Time Of Procedure</time_frame>
        <posting_date>06/2019</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event data are collected from the point of enrollment (consent signed) through a subject's 2 year visit.</time_frame>
      <desc>Serious Adverse Event:
led to death,
led to a serious deterioration in the health of the subject, resulting in
a life-threatening illness or injury or
a permanent impairment of a body structure or a body function or
in-patient or prolonged hospitalization or
medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function
led to foetal distress, death or congenital abnormality/birth defect.</desc>
      <group_list>
        <group group_id="E1">
          <title>Melody PB1016 Subjects Consented (i.e. Enrolled)</title>
          <description>This study is comprised of a single arm of subjects consented (i.e. enrolled) into the trial. All enrolled subjects were intended to be treated with the Melody TPV PB1016 device. Not all subjects enrolled ultimately received the device.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Valve dysfunction: residual stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Junctional rhythm (greater than or equal to 100 bpm)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>RVOT conduit rupture or dissection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Other device-related adverse event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis, confirmed (positive blood culture)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other respiratory/pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Apnea/hypoventilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage: major</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Access site complication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chad Harris, Sr. Clinical Research Specialist</name_or_title>
      <organization>Medtronic</organization>
      <phone>763-514-9543</phone>
      <email>chad.m.harris@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

